Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

By sjmartinez • September 19, 2024

Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. PMID: 39291206; PMCID: PMC11403052.

Tags: Clinical Trial, felzartamab, Harbor UCLA, MOR202, Nephrology, phase 2, phospholipase A2 receptor, primary membranous nephropathy, Publications

Fungal Als proteins hijack host death effector domains to promote inflammasome signaling

Zhou T, Solis NV, Marshall M, Yao Q, Pearlman E, Filler SG, Liu H. Fungal Als proteins hijack host death effector domains to promote inflammasome[...]

Depressive Symptoms and Left Ventricular Diastolic Dysfunction Among Men and Women with HIV

Martinez C, Haw NJ, Rodriguez VJ, Kizer JR, Post WS, Wu KC, Lima JAC, Wise JM, Alcaide ML, Plankey M, Konkle-Parker D, Kozlova S, Fischl[...]

Integration and Potential Applications of Cardiovascular Computed Tomography in Cardio-Oncology

Erbay MI, Manubolu VS, Stein-Merlob AF, Ferencik M, Mamas MA, Lopez-Mattei J, Baldassarre LA, Budoff MJ, Yang EH. Integration and Potential Applications of Cardiovascular Computed[...]